Tuesday is off to a strong start.
We’re seeing the major indices firmly in the green as Wall Street returns from Memorial Day weekend.
All 50 U.S. states are now easing lockdowns in some form or another and countries from Japan to the United Kingdom lifting stay-at-home orders and allowing stores and small businesses to reopen, investors are betting the worst of the pandemic, which has taken nearly 350,000 lives around the world, has passed.
And the New York Stock Exchange reopened its trading floor Tuesday but with only about 25% of the normal trader workforce.
The NYSE closed the floor about two months ago due to the coronavirus pandemic and moved to all-electronic trading. Traders returning Tuesday were wearing masks and following social-distancing guidelines.
Driving more positive momentum for investors are positive headlines from Merck and Novavax.
Merck, on Tuesday, announced it was jumping into the global search for a Covid-19 cure and treatment with the development of two different vaccines to prevent it as well as an oral medication to treat it.
The company has kept to the sidelines of the race for a Covid-19 vaccine, said Tuesday it was buying Vienna-based vaccine maker Themis Bioscience for an undisclosed amount, and would collaborate with research nonprofit IAVI to develop two separate vaccines.
And then there’s Novovax.
The company has begun enrolling patients in a trial for its coronavirus vaccine candidate.
The Phase 1 portion of the trial will enroll about 130 healthy participants 18 to 59 years of age at two sites in Australia. The trial will evaluate the safety and effectiveness of the company's vaccine candidate, NVX-CoV2373.
Jim Cramer's word of advice for picking stocks? "Be really careful," Cramer warned. Catch his full breakdown in the video above.